anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to an application method of aluminum foil materials as warmer materials to external slimming drug. The aluminum foil materials of OPP (oriented polypropylene)/VMPET (vacuum aluminum-plating polyethylene terephthalate)/LLDPE (linear low density polyethylene) through compounding. In the VMPET, a coating is arranged between an aluminum plating layer and PET (polyethylene terephthalate), and ventilation holes are distributed in the aluminum foil materials. The aluminum foil materials have the advantages that the coating is firstly coated on the surface of an aluminum plating base material PET film, and the vacuum aluminum plating is carried out, so the coating is arranged between the aluminum plating layer and the PET film and realizes the effect of a buffer layer, the damage to the aluminum plating layer is reduced, the coating is used as the warmer materials for improving the action effect of the external slimming drug, and the effect exerting of the slimming drug is promoted through an external heat source. The slimming drug adopted in the application method consists of 10 to 30g of Xiangfu, 10 to 30g of rhizoma alismatis, 10 to 30g of angelica sinensis, 10 to 30g of betel nut, 10 to 30g of borneol, 10 to 30g of star anise, 10 to 30g of rhizoma alismatis leaf and 10 to 30g of rhizoma atractylodis. When the external slimming drug is adopted to be smeared at the abdomen of the human body, drug ingredients are permeated into the skin of the human body under the effect that the aluminum foil materials provide heat sources, and the effects of enhancing the metabolism and promoting the microcirculation and fat absorption conversion are reached. The external slimming drug has the characteristics that the medicine use is convenient, the effect is obvious, no rebound is generated, and the food limitation is not needed. The external slimming drug is suitable for the application of subcutaneous fat reduction and weight reduction to patients.
ABSTRACT OF THE DISCLOSURE     The present invention relates to the preparation and isolation of 5-position modified uracil nucleosides and nucleotides and to their use in the synthesis of labeled oligonucleotides useful as nucleic acid probes.  More specifically, the present invention provides for improved methods for the preparation of novel 5-aza uracil nucleoside derivatives wherein a 5-halo-uracil nucleoside is reacted with a bifunctional amine, such as diamine, a sulfhydrylamino compound, or an hydroxyamino compound, to yield the corresponding 5-(aza-aminoalkyl)uracil nucleoside, 5-(aza-sulfhydrylalkyl)uracil nucleoside or 5-(aza-hydroxyalkyl)uracil nucleoside, respectively, and for improved methods for the isolation of the products formed.          These uracil nucleoside derivatives can be used as substrates in a method for preparing novel labeled oligonucleotides of DNA.  Reporter groups can be attached either before or after the preparation of the oligonucleotides.  These reporter group labeled oligonucleotides are especially useful when incorporated into nucleic acid probes which readily can be used in hybridization studies to form hybrids with either DNA or RNA. 06/3675z/46
Elezanumab is a fully human monoclonal antibody, which is directed against repulsive guidance molecule A. The safety, tolerability, pharmacokinetics (PK), and immunogenicity of elezanumab were assessed in 2 Phase 1 clinical studies. The objective of this study was to assess the PK, safety, tolerability, and immunogenicity following intravenous infusion of elezanumab in healthy adult Japanese, Han Chinese, and Caucasian participants as well as Western participants from the single-ascending-dose study. Elezanumab exposures were approximately 20% higher in Japanese and Han Chinese participants compared to White participants without controlling for body weight. After statistically controlling for body weight by including it as a covariate, the PK of elezanumab in White participants were comparable to those in Japanese and Han Chinese participants. The clinical implications of these exposure differences are yet to be determined. All adverse events were assessed by the investigator as having no reasonable possibility of being related to the study drugs and were mild in severity. No positive immunogenicity effect was observed that impacted elezanumab exposure or safety.
PURPOSE:To provide a fine amynologically active particle having effective sensitivity and high stability as a reagent for an amynological inspection for detecting or measuring the component in the body fluid of human or animal or discriminating cells by using an amynologically active particle produced by immobil izing an amynologically active material on a particulate carrier. CONSTITUTION:Titled particles are produced by incorporating a mercapto group into a fine particle of 0.03-10mum average diameters having no hydrophobic groups on the surface except glycidyl acrylate or glycidyl methacrylate unit. The mixing ratio of glycidyl acrylate and glycidyl methacrylate in the stage of manufacturing the fine polymer particles is optional and a preferable result is obtd. if the other copolymer components are added. The effect of adding the copolymer components lies in the control of grain sizes. A hydrophilic monomer, more particularly a water soluble monomer is preferred. Protein is hardly adsorbed on the hydrophilic polymer in an aq. medium; therefore, the fine particles immobilized with the amynologically active material according to this invention are stable to the body fluid of specimen, have difficulty in causing nonspecific agglutination and are free from nonspecific sticking to cells.
PROBLEM TO BE SOLVED: To obtain a prophylactic or a therapeutic agent capable of preventing malignant alteration of cancer, converting malignant cancer into benign cancer and thereby making the cancer treatable and useful for prophylaxis and treatment of the cancer, especially undifferentiated type cancer by including a specific inhibitor. SOLUTION: This prophylactic or therapeutic agent is obtained by including a p38 inhibitor. The inhibitor is preferably a compound obtained by a screening method comprising (A) a step of culturing a cancerated cell in the presence or absence of a compound to be tested and (B) a step of judging the differentiated state after the passage of a prescribed time and having the prophylactic or therapeutic activity. For example, a compound represented by the formula or its pharmacologically acceptable salt can be cited. The cancerated cell in the step A is preferably a cancerated cell in which the p38 tyrosine phosphorylation is accelerated. The oral administration with a tablet, etc., or the parenteral administration with a parenteral injection, etc., can be cited as the form of the prophylactic or therapeutic agent.  The pharmaceutical preparation is produced by a known method using an excipient, etc.
BACKGROUND: Burnout, secondary traumatic stress, and high turnover rates among child mental health clinicians are a challenge, not only for the individual therapist and the organization but also for the successful implementation of evidence-based practices. However, little is known about which and how job-and implementation-related factors are associated with burnout, secondary traumatic stress, and turnover intention as well as compassion satisfaction among child therapists. In the present study, we aimed to explore these factors and related mechanisms by integrating the "professional quality of life" and the "job demands-resources" models of occupational health.
METHODS: We measured the perceived professional quality of life and turnover intention among a national sample of 256 therapists working in Norwegian Child and Adolescence Mental Health Clinics (n = 44) that implemented Trauma-Focused Cognitive Behavior Therapy (TF-CBT). Seventeen Job-and implementation-related resources and demands were also measured using the General Nordic Questionnaire for Psychological and Social Factors at Work and the Implementation Component Questionnaire. Path analysis was used to test whether burnout and compassion satisfaction mediate the relationship between job demands and resources on one hand, and secondary traumatic stress and turnover intention on the other hand.
RESULTS AND DISCUSSION: Results revealed that two job resources, i.e., positive challenges at work and mastery of work, were significant predictors of all professional outcomes. The proposed model was only partly supported. That is, while burnout did mediate the relationship between some job demands (i.e., work-family interference and role conflict) and job resources (i.e., human resource primacy, positive challenges, and mastery of work) with secondary traumatic stress and turnover intention, compassion satisfaction did not mediate the relationship between job resources and turnover intention. Moreover, in addition to their indirect effects via burnout, role conflict and organizational climate (human resource primacy) also directly affected turnover intention. These findings propose that interventions that reduce burnout should be prioritized to improve the professional quality of life and turnover intention among child therapists. Theoretically, it seems that compassion satisfaction and work engagement act differently.
Patients receive cabozantinib PO QD on days 1-28 and enfortumab vedotin IV on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The patients of study group received DHEA 25 mg orally,three times a day before the IVF cycle. Except for IVF, the control group of patients did not receive any pre-treatment.
Pulmonary arterial hypertension (PAH) is a chronic and fatal disease characterized by pulmonary vascular remodeling, similar to the 'Warburg effect' observed in cancer, which is caused by reprogramming of glucose metabolism. Oroxylin A (OA), an active compound derived from Scutellaria baicalensis, which can inhibit glycolytic enzymes [hexokinase 2 (HK2), Lactate dehydrogenase (LDH), and pyruvate dehydrogenase kinase 1 (PDK1) by downregulating aerobic glycolysis to achieve the treatment of liver cancer. To the best of our knowledge, however, the impact of OA on PAH has not been addressed. Consequently, the present study aimed to evaluate the potential protective role and mechanism of OA against PAH induced by monocrotaline (MCT; 55 mg/kg). The mean pulmonary artery pressure (mPAP) was measured using the central venous catheter method; HE and Masson staining were used to observe pulmonary artery remodeling. Non‑targeted metabolomics was used to analyze the metabolic pathways and pathway metabolites in MCT‑PAH rats. Western Blot analysis was employed to assess the levels of glucose transporter 1 (Glut1), HK2), pyruvate kinase (PK), isocitrate dehydrogenase 2 (IDH2), pyruvate dehydrogenase kinase 1(PDK1), and lactate dehydrogenase (LDH) protein expression in both lung tissue samples from MCT‑PAH rats. The results demonstrated that intragastric administration of OA (40 and 80 mg/kg) significantly decreased mPAP from 43.61±1.88 mmHg in PAH model rats to 26.51±1.53 mmHg and relieve pulmonary artery remodeling. Untargeted metabolomic analysis and multivariate analysis indicated abnormal glucose metabolic pattern in PAH model rats, consistent with the Warburg effect. OA administration decreased this effect on the abnormal glucose metabolism. The protein levels of key enzymes involved in glucose metabolism were evaluated by western blotting, which demonstrated that OA could improve aerobic glycolysis and inhibit PAH by decreasing the protein levels of Glut1, HK2, LDH, PDK1 and increasing the protein levels of PK and IDH2. In conclusion, OA decreased MCT‑induced PAH in rats by reducing the Warburg effect.
BACKGROUND: Gunshot wounds (GSW) to the heart are lethal, and most patients die before they arrive to the hospital. Survival decreases with number of cardiac chambers involved. We report a case of a 17-year-old male who survived a GSW injury involving two cardiac chambers with acute severe tricuspid regurgitation (TR) who subsequently developed cardiogenic shock requiring extracorporeal membrane oxygenation (ECMO) support.
CASE PRESENTATION: A 17-year-old male sustained a single gunshot wound to the left chest, resulting in pericardial tamponade and right hemothorax. Emergency sternotomy revealed injury to the right ventricle and inferior cavoatrial junction with the adjacent pericardium contributing to a right hemothorax. The cardiac injuries were repaired primarily. Tricuspid regurgitation was confirmed immediately postoperatively. Five days after presentation, the patient developed cardiogenic shock secondary to TR requiring emergent stabilization with ECMO. He subsequently underwent successful tricuspid valve replacement.
CONCLUSIONS: This is the first report to our knowledge of successful ECMO support of severe TR due to gunshot injury to the heart.
The goals of this clinical trial includes: ① To confirm whether LRRFS after reduced-dose radiotherapy in combination with chemotherapy and immunotherapy is non-inferior to LRRFS after conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response; ② To explore the impact of reduced-dose radiotherapy on 3-year OS, 3-year PFS, 3-year DMFS, 3-year LRFS and 3-year RRFS for treatment-sensitive stage III NPC patients screened out according to the treatment response; ③ To explore the impact of reduced-dose radiotherapy on radiotherapy complications and quality of life; ④ To explore the interaction between different clinical factors and the impact of reduced-dose radiotherapy on the prognosis of patients; ⑤ To explore the biomarkers of sensitivity to chemotherapy and radiotherapy for patients with nasopharyngeal carcinoma and the underlying mechanism.

For these purposes, we plan to prospectively enroll stage III NPC patients from 9 hospitals in China. The participants will receive 3 cycles of induction chemotherapy (GP regimen + Camrelizumab) followed by intensity-modulated radiation therapy. 2 cycles of concurrent chemotherapy will be administered during the radiotherapy. Patients' treatment response will be evaluated with MRI examination after 27 fractions of radiotherapy. If the treatment response after 27 fractions of radiotherapy is complete remission, the participants will be randomized into reduced-dose radiotherapy group and conventional-dose radiotherapy group. If the treatment response after 27 fractions of radiotherapy is not complete remission, the participants will be assigned to the unenrolled group. All the participants in the unenrolled group will receive conventional-dose radiotherapy. After the radiotherapy, all the participants will receive 9 cycles of Camrelizumab immunotherapy. Besides, all the participants in the unenrolled group will also receive metronomic adjuvant capecitabine chemotherapy for 1 year. The prognosis, complication, and quality of life will be compared between the reduced-dose radiotherapy group and the conventional-dose radiotherapy group.
BACKGROUND: Focal task-specific dystonia is a form of isolated focal dystonia that occurs during the performance of a specific skilled motor task. The occurrence of oromandibular dystonia (OMD) specifically in association with the recitation of Quranic verses have been rarely reported in the literature, in non-native Arabic-speaking patients. This case series describe a rare type of focal task-specific dystonia that occurs exclusively by reciting Quran in native Arabic-speaking patients, which has never been reported, to the best of our knowledge.
METHODS: In this case series, we identified five patients with new-onset OMD that was exclusively induced by reciting Quran. Cases were evaluated in our Movement Disorders outpatient clinic at Ibn Sina hospital; the main tertiary neurology center in Kuwait, between 2015 and 2023.
RESULTS: Five cases (3 males, 2 females) were identified in this study. Mean age of onset of the symptoms was 52.3 ± 4.1 years, while the median duration of the symptoms prior to diagnosis was 3 years. All patients were native Arab-speaking, with no previous history of other types of dystonia. No identifiable risk factors could be obtained including exposure to dopamine blocking agents or antipsychotics, or history of oral or dental surgery. Patients underwent a full clinical, laboratory, and radiological evaluation. All patients had OMD dystonia in varying forms and severity, while two patients had additional spasmodic dysphonia/ blepharospasm on progressive recitation. Most patients had minimal improvement with combination of oral medications and speech therapy. Four patients received botulinum toxin injections with better results.
DISCUSSION: The mental and physical stress in attempting to recite the Quranic verses could have contributed to the development of OMD. Moreover, the increased demand on the muscles of the jaw, lips, and tongue during recitation can trigger the dystonic symptoms.
HIGHLIGHTS: OMD exclusively during Quran recitation is a rare phenomenon, and expands the spectrum of task-specific focal dystonia described in the literature. It was found to be distressing to the patients and a challenge to treat. Prompt recognition could minimize unnecessary testing and procedures, and facilitate earlier treatment.
Dexmedetomidine (Dex) has been used in surgery to improve patients' postoperative cognitive function. However, the role of Dex in stress-induced anxiety-like behaviors and cognitive impairment is still unclear. In this study, we tested the role of Dex in anxiety-like behavior and cognitive impairment induced by acute restrictive stress and analyzed the alterations of the intestinal flora to explore the possible mechanism. Behavioral and cognitive tests, including open field test, elevated plus-maze test, novel object recognition test, and Barnes maze test, were performed. Intestinal gut Microbe 16S rRNA sequencing was analyzed. We found that intraperitoneal injection of Dex significantly improved acute restrictive stress-induced anxiety-like behavior, recognition, and memory impairment. After habituation in the environment, mice (male, 8 weeks, 18-23 g) were randomly divided into a control group (control, N = 10), dexmedetomidine group (Dex, N = 10), AS with normal saline group (AS + NS, N = 10) and AS with dexmedetomidine group (AS + Dex, N = 10). By the analysis of intestinal flora, we found that acute stress caused intestinal flora disorder in mice. Dex intervention changed the composition of the intestinal flora of acute stress mice, stabilized the ecology of the intestinal flora, and significantly increased the levels of Blautia (A genus of anaerobic bacteria) and Coprobacillus. These findings suggest that Dex attenuates acute stress-impaired learning and memory in mice by maintaining the homeostasis of intestinal flora.
BACKGROUND: Chronic obstructive pulmonary disease (COPD) contributes to the incidence and prognosis of lung cancer. The presence of COPD significantly increases the risk of lung squamous cell carcinoma (LSCC). COPD may promote an immunosuppressive microenvironment in LSCC by regulating the expression of immune-inhibitory factors in T cells, although the mechanisms remain unclear. In this study, we aimed to decipher the tumour microenvironment signature for LSCC with COPD at a single-cell level.
METHODS: We performed single-cell RNA sequencing on tumour tissues from LSCC with or without COPD, then investigated the features of the immune and tumour cells. We employed multiple techniques, including multispectral imaging, flow cytometry, tissue microarray analysis, survival analysis, co-culture systems and in vitro and in vivo treatment experiments, to validate the findings obtained from single-cell analyses.
RESULTS: LSCC with COPD showed increased proportions of tumour-associated macrophages (TAMs) and higher levels of CD8+ T cell exhaustion molecules, which contributed to an immunosuppressive microenvironment. Further analysis revealed a critical cluster of CD74+ tumour cells that expressed both epithelial and immune cell signatures, exhibited a stronger capacity for tumorigenesis and predicted worse overall survival. Notably, migration inhibitory factor (MIF) secreted by TAMs from LSCC with COPD may promote the activation of CD74. MIF-CD74 may interact with CD8+ T cells and impair their anti-tumour activity by regulating the PI3K-STAT3-programmed cell death-1 ligand 1 signalling pathway, facilitating tumour proliferation and immune evasion.
CONCLUSIONS: Our comprehensive picture of the tumour ecosystem in LSCC with COPD provides deeper insights into relevant immune evasion mechanisms and potential targets for immunotherapy.
HIGHLIGHT: Our results demonstrated higher proportions of tumour-associated macrophages (TAMs) and higher levels of exhaustion molecules in CD8+ T cells in the microenvironment of LSCC with COPD. CD74+tumour cells were associated with poor disease prognosis. Migration inhibitory factor (MIF)-CD74 may interact with CD8+ T cells and impair their anti-tumour activity by regulating the PI3K-STAT3-PD-L1 signalling pathway, facilitating immune evasion.
Participants in Arm 1 will be posted the Under \& Over study pack (1) and asked to complete the Under \& Over tool daily for up to 30 minutes per day, 5 days per week for 3 months. They will be instructed to follow the instruction booklet and complete each pattern in the specific order described in the booklet.
PURPOSE:To allow liposome to take in more contents with less lipid per one liposome and to lower the concn. of liposome suspended and the viscosity of the suspension by regulating the average outside diameter of particles of liposome contg. a taken-in soln. to 180-300nm. CONSTITUTION:Liposome membrane forming lipid is suspended in an aq. hemoglobin soln. until the average outside diameter of particles becomes 180-300nm. The resulting suspension is subjected to high ejection treatment to obtain desired liposome. The concn. of liposome suspended is lowered and a load on a circulatory organ is relieved at the time of injection into blood.
The invention comprises systems, methods and computerized data management device for creating and using data relating to a medical or non-medical product or device to enhance the safety of the product or device. Vast amounts of data is received regarding adverse events associated with a particular product or device, which data is analyzed in light of known adverse events associated with the product or device. At least one proprietary database of newly discovered adverse event information is created and utilized, and new characteristics of or uses for the product or device are determined. Adverse event information is gathered for a large number of population sub-groups. The system may also be programmed to incorporate the information into intellectual property and contract documents. Manufacturers and/or distributors can include the proprietary information in consumer safety information, which accompanies the product or device, or which is provided to patients, users, consumers and the like, or in the case of certain medical products or devices, to prescribers of those products or devices.
PURPOSE: A novel peptide, variant or pharmaceutically acceptable salt thereof is provided to treat or/and prevent degenerative disk disorder, fibrosis, cancer and/or glomerular diseases. CONSTITUTION: A novel peptide comprises an amino acid sequence of L-(Q or N)-VV-(Y, F, or W)-L-(H, K, or R). A composition for preventing and treating degenerative disk contains the novel peptide or pharmaceutically acceptable salt thereof. A composition for treating fibrosis contains the novel peptide or pharmaceutically acceptable salt thereof. A composition for treating cancer contains the novel peptide or pharmaceutically acceptable salt thereof. The novel peptide comprises an amino acid sequence of sequence number 1.